Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies for high unmet medical needs. Its commercial products include Fanapt (iloperidone) for schizophrenia and bipolar I disorder, HETLIOZ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome, PONVORY (ponesimod) for relapsing forms of multiple sclerosis, and NEREUS (tradipitant) for prevention of vomiting induced by motion. The company also has pipeline candidates including Bysanti (milsaperidone) and imsidolimab.
Q2 FY2026 — expected 2026-09-28
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001628280-26-007460 | EDGAR | 88K words |
| 2025-02-14 | 2024-12-31 | 0001628280-25-005761 | EDGAR | — |
| 2024-02-08 | 2023-12-31 | 0001628280-24-003785 | EDGAR | — |
| 2023-02-09 | 2022-12-31 | 0001628280-23-002857 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001628280-22-003629 | EDGAR | — |
| 2021-02-11 | 2020-12-31 | 0001347178-21-000005 | EDGAR | — |
| 2020-02-26 | 2019-12-31 | 0001347178-20-000003 | EDGAR | — |
| 2019-02-19 | 2018-12-31 | 0001347178-19-000003 | EDGAR | — |
| 2018-02-15 | 2017-12-31 | 0001193125-18-046425 | EDGAR | — |
| 2017-02-17 | 2016-12-31 | 0001193125-17-047317 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001628280-25-047317 | EDGAR | 26K words |
| 2025-07-31 | 2025-06-30 | 0001628280-25-036861 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001628280-25-023448 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001628280-24-045970 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001628280-24-033866 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001628280-24-021952 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001628280-23-038029 | EDGAR | — |
| 2023-07-28 | 2023-06-30 | 0001628280-23-026000 | EDGAR | — |
| 2023-05-03 | 2023-03-31 | 0001628280-23-015267 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001628280-22-027951 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-020848 | EDGAR | — |
| 2022-05-06 | 2022-03-31 | 0001628280-22-012834 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001628280-26-023222 | EDGAR | 1K words |
| 2026-03-10 | 0001628280-26-016516 | EDGAR | — |
| 2026-02-23 | 0001628280-26-010376 | EDGAR | — |
| 2026-02-19 | 0001628280-26-009805 | EDGAR | — |
| 2026-02-11 | 0001628280-26-007256 | EDGAR | — |
| 2026-01-08 | 0001628280-26-001273 | EDGAR | — |
| 2025-12-31 | 0001628280-25-059155 | EDGAR | — |
| 2025-12-04 | 0001628280-25-055393 | EDGAR | — |
| 2025-11-28 | 0001628280-25-054225 | EDGAR | — |
| 2025-10-29 | 0001628280-25-047112 | EDGAR | — |
362 total filings indexed. 330 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001347178 |
| Ticker | VNDA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.vandapharma.com |
| Listed | 2006-04-12 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report